An Evaluation of Off-Label Fenoldopam Use in the Neonatal Intensive Care Unit

ABSTRACT

We analyzed the effect of off-label fenoldopam (FDM) therapy on electrolyte balance, renal function, blood pressure, and urinary output in neonatal patients. We performed a retrospective review of 22 neonates treated with FDM in two neonatal intensive care units. Primary outcome compared physiological status 24 hours before FDM therapy to the first 24 hours of FDM therapy. Electrolytes, blood urea nitrogen (BUN), creatinine, fluid intake, respiratory support, blood pressure, and heart rate were also compared. FDM was used to treat oliguria and anasarca. Seven infants were supported with extracorporeal membrane oxygenation. Gestation ranged 24 to 39 weeks (median 37) and postnatal age, 1 to 89 days (median 10). FDM dose increased over time (median initial dose 0.10 μg/kg/min versus 0.20 at 48 hours). FDM therapy had no effect on serum creatinine, electrolytes, or cardiopulmonary function but was associated with a significant increase in BUN (p = 0.008). Urine output did not increase significantly for the group as a whole (paired t test) but did significantly increase during the initial 24-hour infusion among oliguric infants. Low-dose FDM did not improve urine output in critically ill neonates as a whole. There were no apparent adverse cardiopulmonary or metabolic effects from FDM use in this limited population. Future FDM use in the context of a randomized prospective trial appears warranted in the early management of infants with oliguria.

KEYWORDS

Neonate - oliguria - fenoldopam - renal

REFERENCES

• 1 Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety.  Expert Opin Drug Saf. 2006;  5 703-718
• 2 Fryckstedt J, Svensson L, Lindén M, Aperia A. The effect of dopamine on adenylate cyclase and Na+, K(+)-ATPase activity in the developing rat renal cortical and medullary tubule cells.  Pediatr Res. 1993;  34 308-311
• 3 Guzman J, Rosado A, Kruse J. Dopamine-1 receptor stimulation attenuates the vasoconstrictive response to gut ischemia.  J Appl Physiol. 2001;  91 596-602
• 4 Halpenny M, Markos F, Snow H et al.. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs.  Crit Care Med. 2001;  29 855-860
• 5 Strauser L, Pruitt R, Tobias J. Initial experience with fenoldopam in children.  Am J Ther. 1999;  6 283-288
• 6 Costello J, Thiagarajan R, Dionne R et al.. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics.  Pediatr Crit Care Med. 2006;  7 28-33
• 7 Moffett B, Mott A, Nelson D, Goldstein S, Jefferies J. Renal effects of fenoldopam in critically ill pediatric patients: a retrospective review.  Pediatr Crit Care Med. 2008;  9 403-406
• 8 Brienza N, Malcangi V, Dalfino L et al.. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.  Crit Care Med. 2006;  34 707-714
• 9 Morelli A, Ricci Z, Bellomo R et al.. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.  Crit Care Med. 2005;  33 2451-2456
• 10 Cogliati A, Vellutini R, Nardini A et al.. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study.  J Cardiothorac Vasc Anesth. 2007;  21 847-850
• 11 Morelli A, Rocco M, Conti G et al.. Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock.  Anesthesiology. 2004;  101 576-582
• 12 Moffett B, Orellana R. Use of fenoldopam to increase urine output in a patient with renal insufficiency secondary to septic shock: a case report.  Pediatr Crit Care Med. 2006;  7 600-602